本报记者 刘钊 对不少肿瘤患者而言，最难的并非某一次治疗本身，而是出院后的"漫长空窗期"：复查节点如何安排、 化疗副作用如何监测、检验报告怎么看、夜间突发不适找谁咨询……现实中，医疗服务的"时空限 制"与"服务断层"，常常让患者在院外陷入"失管"困局。 在此背景下，盈康生命科技股份有限公司（以下简称"盈康生命"）发布肿瘤全周期管理智能体，并提出 以此为核心载体推进战略升级，在医疗服务板块实现从诊疗场所到提供健康导航系统的主动健康管理生 态平台。 围绕战略升级的底层逻辑、产品如何真正实现"线上+线下"融合以及商业闭环如何跑通等问题，《证券 日报》记者近日专访了盈康生命董事兼总经理马安捷。 打造"专属AI私人医生" 盈康生命成立于1998年，于2010年登陆深交所创业板，2019年公司实际控制人变更为海尔集团。在医疗 服务端，公司经营及管理着11家医疗机构。在器械端，公司围绕肿瘤"预/诊/治/康"关键场景布局放射治 疗、生命支持、影像增强、慢病治疗等产品线。 这种"从工具到供给侧变革"的判断，也体现在公司对AI底座的描述上。马安捷提到，盈康生命正在 以"盈康大脑"为智慧中枢，形成"算力与数据湖—能力组件—智能交互 ...

Core Insights - The core focus of the news is the launch of the AI-driven Tumor Full-Cycle Management Intelligent System by Yingkang Life Technology Co., Ltd., aimed at transforming cancer care through technology and collaboration with various partners [1][3]. Company Developments - Yingkang Life has officially released a strategic product, the Tumor Full-Cycle Management Intelligent System, during the AI Tumor Full-Cycle Health Management Development Forum [1]. - The intelligent system aims to provide each cancer patient with a dedicated AI personal doctor, marking a significant shift from a comprehensive medical group to a technology-driven health solution provider [3]. - The system integrates five core functionalities covering early screening, diagnosis, treatment, rehabilitation, and ecological linkage, utilizing an "online + offline" model to address the entire patient journey [3]. Industry Context - In 2022, approximately 4.8 million new cancer cases were reported in China, accounting for 24% of the global total, highlighting the urgent need for continuous cancer care due to an aging population [4]. - Traditional medical services face challenges such as inefficiencies in hospital visits and difficulties in interpreting medical reports, which the new intelligent system aims to resolve [4]. - The industry consensus is shifting towards a full-cycle systemic paradigm in cancer treatment, moving away from fragmented hospital-centric models [5]. Competitive Advantages - Yingkang Life possesses a unique competitive edge through a combination of resources, technology, and service capabilities, which are difficult for competitors to replicate [6]. - The company operates 11 hospitals and care institutions, creating a comprehensive regional medical center and collaborative network [6]. - The integration of AI and digital strategies has positioned Yingkang Life to leverage extensive real-world data from nearly 200,000 cancer patients annually, enhancing the training of medical AI [6][7]. Technological Innovations - Yingkang Life has initiated a digital transformation strategy, achieving interconnectivity among core systems and establishing a "data lake" for enhanced data utilization [7]. - The company is set to enter the "AI Application 3.0 phase" by early 2025, utilizing advanced AI models to improve healthcare delivery [7]. - The intelligent system is designed to provide personalized and empathetic healthcare services, addressing patient needs effectively [8]. Ecosystem Collaboration - The forum featured contributions from partners like United Imaging Healthcare, Ant Health, and Huimei Technology, emphasizing collaborative efforts in advancing AI in healthcare [9]. - Huimei Technology has developed AI solutions that have been implemented in over 1,200 hospitals, focusing on critical clinical processes in oncology [9]. - Ant Health aims to enhance industry collaboration and provide accessible AI health services, aligning with Yingkang Life's vision for a comprehensive health ecosystem [9]. Future Outlook - The Tumor Health Management Intelligent System platform is expected to be fully operational by 2026, with plans to cover one million cancer patients over the next 3-5 years [10]. - The new strategy is anticipated to lead to a valuation restructuring in the capital market, positioning Yingkang Life as a growth-oriented and scarce investment opportunity [10]. - The "online + offline" integration model is expected to enhance patient satisfaction and operational efficiency, driving revenue growth and long-term sustainability for the company [10].

AI肿瘤全周期健康管理生态平台启动） 本报记者 刘钊 12月19日，盈康生命科技股份有限公司（以下简称"盈康生命"）在北京举办"AI肿瘤全周期健康管理发 展论坛"。论坛聚焦人工智能赋能肿瘤防治体系变革，来自政策研究、临床医学、科技企业及产业投资 等多领域的专家学者与生态伙伴，共同探讨AI驱动下肿瘤防控新模式的构建。 盈康生命董事兼总经理马安捷称，"公司使命将变成以科技为驱动，为用户提供全场景、全周期的整合 式的健康管理服务。我们将围绕着肿瘤、血液、居家等场景，在医疗服务和医疗器械双轮驱动的基础 上，以科技创新为底座，构建一个AI驱动下的健康解决方案平台"。有业内人士表示，此举将为公司发 展注入全新动能，且可能颠覆传统医疗服务行业生态。 （盈康生命 与传统的互联网医院模式和线下医院的数字化升级不同，盈康生命肿瘤全周期健康管理智能体真正实现 了线上线下的融合，形成了肿瘤全周期健康管理的新业态。 据了解，盈康生命旗下医院每年服务近20万肿瘤患者。目前，我国肿瘤防治事业面临的系统性挑战，同 时叠加人口老龄化趋势，社会对肿瘤长期、连续照护的需求日益迫切。因而，突破传统以医院为中心 的"片段化"诊疗模式，构建覆盖预防、诊 ...

12月19日，盈康生命科技股份有限公司在北京举办"AI肿瘤全周期健康管理发展论坛"。论坛聚焦人工智能赋能肿瘤防治体系变革，来自政策研究、临 床医学、科技企业及产业投资等多领域的专家学者与生态伙伴，共同探讨AI驱动下肿瘤防控新模式的构建。 与传统的互联网医院模式和线下医院的数字化升级不同，盈康生命肿瘤全周期健康管理智能体真正实现了线上线下的融合，形成了肿瘤全周期健康管 理的新业态。 据了解，盈康生命旗下医院每年服务近20万肿瘤患者。目前，我国肿瘤防治事业面临的系统性挑战，同时叠加人口老龄化趋势，社会对肿瘤长期、连 续照护的需求日益迫切。因而，突破传统以医院为中心的"片段化"诊疗模式，构建覆盖预防、诊断、治疗、康复全周期的系统性新范式已成为行业共 识。 自2025年4月发布AI创新应用平台后，肿瘤健康管理智能体的发布也标志着盈康生命AI战略的再升级，即从AI工具到场景产品的升级。依托该智能 体，盈康生命将于2026年正式对外发布肿瘤垂直领域的APP，未来三到五年预计服务百万计用户量，并围绕患者、医生及药械企业需求开发生态服务 产品，实现生态闭环。 财经频道更多独家策划、专家专栏，免费查阅>>责任编辑：栎树 （盈康 ...